Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Recro Pharma Inc (REPH)

Recro Pharma Inc (REPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 382,091
  • Shares Outstanding, K 22,730
  • Annual Sales, $ 77,350 K
  • Annual Income, $ -79,720 K
  • 60-Month Beta -0.35
  • Price/Sales 4.92
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.30
  • Number of Estimates 2
  • High Estimate -0.16
  • Low Estimate -0.43
  • Prior Year -0.58
  • Growth Rate Est. (year over year) +48.28%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.67 +14.59%
on 11/22/19
17.75 -5.30%
on 11/21/19
-0.32 (-1.87%)
since 11/13/19
3-Month
10.73 +56.66%
on 10/02/19
18.20 -7.63%
on 11/13/19
+4.82 (+40.20%)
since 09/13/19
52-Week
5.53 +203.97%
on 03/25/19
18.20 -7.63%
on 11/13/19
+9.24 (+122.06%)
since 12/13/18

Most Recent Stories

More News
Recro Completes Separation of Baudax Bio and Becomes a Dedicated Contract Development and Manufacturing Organization

Recro Capitalizing on Strong and Growing CDMO Business

REPH : 16.81 (+0.36%)
Baudax Bio(TM) Launches as a New Pharmaceutical Company Aimed at Advancing Promising, Non-Opioid Analgesic Therapies

Company Launches with $19 Million in Funding and Rights to IV Meloxicam, Along with Other Clinical-Stage Pipeline Assets

REPH : 16.81 (+0.36%)
BXRX : 6.05 (-3.97%)
Recro Pharma Announces Effectiveness of Baudax Bio Form 10 Registration Statement

Separation of Baudax Bio as Independent Company Expected to be Completed With Distribution on November 21, 2019

REPH : 16.81 (+0.36%)
Recro Pharma (REPH) Reports Q3 Loss, Tops Revenue Estimates

Recro Pharma (REPH) delivered earnings and revenue surprises of -46.15% and 27.38%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

REPH : 16.81 (+0.36%)
Recro Pharma: 3Q Earnings Snapshot

MALVERN, Pa. (AP) _ Recro Pharma Inc. (REPH) on Friday reported a loss of $4.3 million in its third quarter.

REPH : 16.81 (+0.36%)
Recro Pharma Reports Third Quarter 2019 Financial Results

CDMO Business Achieves 37% Growth in 2019 Year to Date Revenues; Consolidated Company Achieves Profitability from Operations, Turns Cash Flow Positive and Raises 2019 Revenue Guidance to $98-100 Million...

REPH : 16.81 (+0.36%)
Recro Pharma to Report Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 8, 2019

Recro Pharma, Inc. (NASDAQ:REPH) today announced that it will report third quarter financial results on Friday, November 8, 2019. Recro's management team will host a conference call and audio webcast...

REPH : 16.81 (+0.36%)
Recro Pharma's Board of Directors Approves Separation of Acute Care Business Segment and Declares Special Dividend Distribution of Baudax Bio Common Stock

Recro Pharma, Inc. (NASDAQ:REPH), a specialty pharmaceutical company with a high-performing revenue generating contract development and manufacturing (CDMO) division, today announced that its board of...

REPH : 16.81 (+0.36%)
FDA Grants Appeal to Recro Pharma for IV Meloxicam New Drug Application

Received Positive Response from FDA Regarding IV Meloxicam Formal Dispute Resolution Request

REPH : 16.81 (+0.36%)
Buy These 7 Small Drugmakers to Boost Your Portfolio's Health

Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity have kept small drugmakers afloat in a competitive market.

NBIX : 110.59 (-0.75%)
GNCA : 2.19 (-0.90%)
REPH : 16.81 (+0.36%)
ZTS : 124.45 (+0.10%)
CPRX : 4.43 (+2.55%)
FLXN : 19.80 (-4.92%)
VRCA : 14.77 (+1.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade REPH with:

Business Summary

Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company. It develops non-opioid therapeutics for the treatment of pain in the post-operative setting. The company is developing intranasal formulation of Dexmedetomidine (Dex) for the treatment of post-operative pain and cancer breakthrough...

See More

Key Turning Points

2nd Resistance Point 17.32
1st Resistance Point 17.06
Last Price 16.81
1st Support Level 16.51
2nd Support Level 16.21

See More

52-Week High 18.20
Last Price 16.81
Fibonacci 61.8% 13.36
Fibonacci 50% 11.86
Fibonacci 38.2% 10.37
52-Week Low 5.53

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar